kynurenine has been researched along with Idiopathic Parkinson Disease in 42 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases (NDs), presenting a broad range of symptoms from motor dysfunctions to psychobehavioral manifestations." | 6.66 | Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. ( Tanaka, M; Toldi, J; Vécsei, L, 2020) |
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases (NDs), presenting a broad range of symptoms from motor dysfunctions to psychobehavioral manifestations." | 2.66 | Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. ( Tanaka, M; Toldi, J; Vécsei, L, 2020) |
| "Parkinson's disease is a common progressive neurodegenerative disorder presenting with characteristic motor symptoms." | 2.53 | Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System. ( Fülöp, F; Majláth, Z; Toldi, J; Vécsei, L, 2016) |
| " Although levodopa continues to be the gold standard of symptomatic efficacy for treatment of the cardinal motor features, its chronic use is associated with potentially disabling motor complications." | 2.46 | Medical treatment of Parkinson's disease: today and the future. ( Gárdián, G; Vécsei, L, 2010) |
| "L-kynurenine is a central compound of this pathway since it can change to the neuroprotective agent kynurenic acid or to the neurotoxic agent quinolinic acid." | 2.43 | Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. ( Németh, H; Toldi, J; Vécsei, L, 2006) |
| " To exploit possibilities of TDO inhibitory treatment, development of further selective TDO inhibitor compounds with good bioavailability features and models adequately replicating PD symptoms of systemic origin should be prioritized." | 1.62 | Tryptophan 2,3-dioxygenase, a novel therapeutic target for Parkinson's disease. ( Boros, FA; Vécsei, L, 2021) |
| "The kynurenine (KYN) pathway plays an important role in degrading molecules responsible for oxidative stress in the central nervous system (CNS), but can also have neurotoxic effects." | 1.56 | Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease. ( Iwaoka, K; Kato, K; Maeda, T; Otsuka, C; Takahashi, K; Terayama, Y; Yamahara, K, 2020) |
| "The pathogenesis of Parkinson's disease (PD) remains to be elucidated." | 1.48 | Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson's Disease. ( Chang, KH; Chen, CM; Cheng, ML; Huang, CY; Tang, HY; Wu, YR, 2018) |
| "L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective drug in the symptomatic treatment of Parkinson's disease, but chronic use is associated with L-DOPA-induced dyskinesia in more than half the patients after 10 years of treatment." | 1.46 | Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia. ( Andersen, AD; Binzer, M; Blaabjerg, M; Faergeman, NJ; Gramsbergen, JB; Havelund, JF; Heegaard, NHH; Stenager, E, 2017) |
| "In 22 patients with Parkinson's disease (PD) and in 11 age-matched controls, serum and cerebrospinal fluid (CSF) neopterin concentrations were measured by ELISA." | 1.31 | Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. ( Fuchs, D; Leblhuber, F; Widner, B, 2002) |
| "In untreated patients with Parkinson's disease (PD), the total (free and conjugated) serotonin (5-HT) and dopamine (DA) concentrations in the cerebrospinal fluid decreased significantly." | 1.29 | Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. ( Abe, T; Hamato, H; Takahashi, J; Takahashi, S; Tohgi, H, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.38) | 18.7374 |
| 1990's | 4 (9.52) | 18.2507 |
| 2000's | 5 (11.90) | 29.6817 |
| 2010's | 16 (38.10) | 24.3611 |
| 2020's | 16 (38.10) | 2.80 |
| Authors | Studies |
|---|---|
| Boros, FA | 1 |
| Vécsei, L | 11 |
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Endepols, H | 1 |
| Zlatopolskiy, BD | 1 |
| Zischler, J | 1 |
| Alavinejad, N | 1 |
| Apetz, N | 1 |
| Vus, S | 1 |
| Drzezga, A | 1 |
| Neumaier, B | 1 |
| Venkatesan, D | 1 |
| Iyer, M | 1 |
| S, RW | 1 |
| Narayanasamy, A | 1 |
| Kamalakannan, S | 1 |
| Valsala Gopalakrishnan, A | 1 |
| Vellingiri, B | 1 |
| Qin, W | 1 |
| Shi, Y | 1 |
| Chen, W | 1 |
| Jia, X | 1 |
| Asakawa, T | 1 |
| Martins, LB | 1 |
| Silveira, ALM | 1 |
| Teixeira, AL | 1 |
| Török, N | 1 |
| Maszlag-Török, R | 1 |
| Molnár, K | 1 |
| Szolnoki, Z | 1 |
| Somogyvári, F | 1 |
| Boda, K | 1 |
| Tanaka, M | 2 |
| Klivényi, P | 4 |
| Fathi, M | 1 |
| Vakili, K | 1 |
| Yaghoobpoor, S | 1 |
| Tavasol, A | 1 |
| Jazi, K | 1 |
| Hajibeygi, R | 1 |
| Shool, S | 1 |
| Sodeifian, F | 1 |
| Klegeris, A | 1 |
| McElhinney, A | 1 |
| Tavirani, MR | 1 |
| Sayehmiri, F | 1 |
| Chen, P | 1 |
| Geng, X | 1 |
| Hajihassani, A | 1 |
| Nourazarian, A | 1 |
| Nikanfar, M | 1 |
| Laghousi, D | 1 |
| Khaki-Khatibi, F | 1 |
| Iwaoka, K | 1 |
| Otsuka, C | 1 |
| Maeda, T | 1 |
| Yamahara, K | 1 |
| Kato, K | 1 |
| Takahashi, K | 2 |
| Terayama, Y | 1 |
| Toldi, J | 7 |
| Bai, JH | 1 |
| Zheng, YL | 1 |
| Yu, YP | 1 |
| Heilman, PL | 1 |
| Wang, EW | 1 |
| Lewis, MM | 1 |
| Krzyzanowski, S | 1 |
| Capan, CD | 1 |
| Burmeister, AR | 1 |
| Du, G | 1 |
| Escobar Galvis, ML | 1 |
| Brundin, P | 1 |
| Huang, X | 1 |
| Brundin, L | 1 |
| Pingale, T | 1 |
| Gupta, GL | 1 |
| Behl, T | 1 |
| Kaur, I | 1 |
| Sehgal, A | 1 |
| Singh, S | 1 |
| Bhatia, S | 1 |
| Al-Harrasi, A | 1 |
| Zengin, G | 1 |
| Bumbu, AG | 1 |
| Andronie-Cioara, FL | 1 |
| Nechifor, AC | 1 |
| Gitea, D | 1 |
| Bungau, AF | 1 |
| Toma, MM | 1 |
| Bungau, SG | 1 |
| Havelund, JF | 1 |
| Andersen, AD | 1 |
| Binzer, M | 1 |
| Blaabjerg, M | 1 |
| Heegaard, NHH | 1 |
| Stenager, E | 1 |
| Faergeman, NJ | 1 |
| Gramsbergen, JB | 1 |
| Robertson, DS | 1 |
| Chang, KH | 1 |
| Cheng, ML | 1 |
| Tang, HY | 1 |
| Huang, CY | 1 |
| Wu, YR | 1 |
| Chen, CM | 1 |
| van den Brink, WJ | 1 |
| Palic, S | 1 |
| Köhler, I | 1 |
| de Lange, ECM | 1 |
| Sorgdrager, FJH | 1 |
| Vermeiren, Y | 1 |
| Van Faassen, M | 1 |
| van der Ley, C | 1 |
| Nollen, EAA | 1 |
| Kema, IP | 1 |
| De Deyn, PP | 1 |
| Lewitt, PA | 1 |
| Li, J | 1 |
| Lu, M | 1 |
| Beach, TG | 1 |
| Adler, CH | 1 |
| Guo, L | 1 |
| Amara, AW | 1 |
| Standaert, DG | 1 |
| Obál, I | 1 |
| Majláth, Z | 2 |
| Luan, H | 1 |
| Liu, LF | 1 |
| Meng, N | 1 |
| Tang, Z | 1 |
| Chua, KK | 1 |
| Chen, LL | 1 |
| Song, JX | 1 |
| Mok, VC | 1 |
| Xie, LX | 1 |
| Li, M | 1 |
| Cai, Z | 1 |
| Mazarei, G | 1 |
| Leavitt, BR | 1 |
| Fülöp, F | 2 |
| Lim, CK | 1 |
| Fernández-Gomez, FJ | 1 |
| Braidy, N | 1 |
| Estrada, C | 1 |
| Costa, C | 1 |
| Costa, S | 1 |
| Bessede, A | 1 |
| Fernandez-Villalba, E | 1 |
| Zinger, A | 1 |
| Herrero, MT | 1 |
| Guillemin, GJ | 1 |
| Vamos, E | 1 |
| Pardutz, A | 1 |
| Gárdián, G | 1 |
| Szabó, N | 1 |
| Kincses, ZT | 1 |
| Zádori, D | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Hartai, Z | 1 |
| Janaky, T | 1 |
| Penke, B | 1 |
| Dux, L | 1 |
| Németh, H | 1 |
| Sternberg, EM | 1 |
| Van Woert, MH | 1 |
| Young, SN | 1 |
| Magnussen, I | 1 |
| Baker, H | 1 |
| Gauthier, S | 1 |
| Osterland, CK | 1 |
| Tohgi, H | 2 |
| Abe, T | 2 |
| Takahashi, S | 2 |
| Takahashi, J | 2 |
| Hamato, H | 2 |
| Stone, TW | 1 |
| Widner, B | 1 |
| Leblhuber, F | 1 |
| Fuchs, D | 1 |
| Beal, MF | 2 |
| Matson, WR | 2 |
| Storey, E | 1 |
| Milbury, P | 2 |
| Ryan, EA | 1 |
| Ogawa, T | 2 |
| Bird, ED | 2 |
| Myers, RH | 1 |
| Saso, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of 12 Weeks Vitamin D Supplementation Combined With Physical Activity on Blood and Functional Parameters and Quality of Life in Parkinson's Disease Patients Treated With Deep Brain Stimulation[NCT04768023] | 50 participants (Actual) | Interventional | 2019-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for kynurenine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
Can kynurenine pathway be considered as a next-generation therapeutic target for Parkinson's disease? An update information.
Topics: 3-Hydroxyanthranilic Acid; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Levodopa; Parki | 2022 |
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleac | 2022 |
Research progress on the kynurenine pathway in the prevention and treatment of Parkinson's disease.
Topics: Central Nervous System; Humans; Inflammation; Kynurenine; Parkinson Disease | 2023 |
Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Biomarkers; Cytokines; Humans; Huntington Disease; Infl | 2020 |
Current and emerging therapeutic targets for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; Humans; Kynurenine; Melanins; Mitochondria; Par | 2021 |
The Footprint of Kynurenine Pathway in Neurodegeneration: Janus-Faced Role in Parkinson's Disorder and Therapeutic Implications.
Topics: Biomarkers; Central Nervous System; Gastrointestinal Microbiome; Humans; Kynurenine; Metabolic Netwo | 2021 |
Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.
Topics: Animals; Biomarkers; Disease Models, Animal; Dopamine Agents; Drug Development; Humans; Hypothalamo- | 2018 |
Mental disturbances in Parkinson's disease and related disorders: the role of excitotoxins.
Topics: Dopamine; Glutamic Acid; Humans; Kynurenine; Mental Disorders; Neuroprotective Agents; Neurotoxins; | 2014 |
Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
Topics: Alzheimer Disease; Animals; Humans; Huntington Disease; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynure | 2015 |
Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Kynurenine; Levodo | 2016 |
Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease.
Topics: Animals; Humans; Kynurenine; Parkinson Disease | 2017 |
The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
Topics: Alzheimer Disease; Animals; Brain; Brain Diseases; Brain Ischemia; Epilepsy; Humans; Huntington Dise | 2009 |
Medical treatment of Parkinson's disease: today and the future.
Topics: Dopamine Agonists; Humans; Kynurenine; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2010 |
Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach.
Topics: Antiparkinson Agents; Humans; Kynurenine; Levodopa; Parkinson Disease; Tryptophan | 2011 |
Kynurenines in Parkinson's disease: therapeutic perspectives.
Topics: Animals; Humans; Kynurenine; Neuroprotective Agents; Parkinson Disease | 2012 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.
Topics: Animals; Humans; Kynurenine; Neurodegenerative Diseases; Parkinson Disease; Quinolinic Acid; Recepto | 2006 |
Kynurenic acid antagonists and kynurenine pathway inhibitors.
Topics: Brain Ischemia; Epilepsy; Excitatory Amino Acid Antagonists; Humans; Kynurenic Acid; Kynurenine; Neu | 2001 |
1 trial available for kynurenine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
Topics: 5-Hydroxytryptophan; Adolescent; Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Therapy, Com | 1980 |
22 other studies available for kynurenine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Tryptophan 2,3-dioxygenase, a novel therapeutic target for Parkinson's disease.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Parkinson Disease; Tryptophan; Tryptophan | 2021 |
Imaging of cerebral tryptophan metabolism using 7-[
Topics: Animals; Disease Models, Animal; Fluorine Radioisotopes; Hippocampus; Kynurenine; Male; Melatonin; O | 2022 |
Genotypic-Phenotypic Analysis, Metabolic Profiling and Clinical Correlations in Parkinson's Disease Patients from Tamil Nadu Population, India.
Topics: alpha-Synuclein; Dopaminergic Neurons; Humans; India; Kynurenine; Mutation; Parkinson Disease | 2022 |
The Involvement of Kynurenine Pathway in Neurodegenerative Diseases.
Topics: Alzheimer Disease; Cross-Sectional Studies; Humans; Kynurenine; Neurodegenerative Diseases; Parkinso | 2023 |
Single Nucleotide Polymorphisms of Indoleamine 2,3-Dioxygenase 1 Influenced the Age Onset of Parkinson's Disease.
Topics: Biomarkers; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Parkinson Disease; Polymorphis | 2022 |
Kynurenine and Beta-Alanine Serum Levels are Associated with the Expression of Wnt Pathway Genes in Patients with Parkinson's Disease.
Topics: Biomarkers; Humans; Kynurenine; Neurodegenerative Diseases; Parkinson Disease; Wnt Signaling Pathway | 2023 |
Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease.
Topics: Aged; Case-Control Studies; Cytokines; Female; Humans; Inflammation; Interferon-gamma; Interleukin-1 | 2020 |
Urinary kynurenine as a biomarker for Parkinson's disease.
Topics: Biomarkers; Cognitive Dysfunction; Humans; Kynurenine; Parkinson Disease; Triglycerides | 2021 |
Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease.
Topics: Biomarkers; Humans; Kynurenine; Parkinson Disease; Substantia Nigra; Tryptophan | 2020 |
Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.
Topics: Adult; Aged; Antiparkinson Agents; Biomarkers; Denmark; Dyskinesia, Drug-Induced; Female; Humans; Ky | 2017 |
Proposed biochemistry of Parkinson's and Alzheimer's diseases.
Topics: Aldehydes; Alzheimer Disease; Aspartic Acid; Betaine; Brain; Disease Progression; Humans; Kynurenine | 2017 |
Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson's Disease.
Topics: Adult; Aged; Cohort Studies; Female; Humans; Kynurenine; Male; Metabolome; Metabolomics; Middle Aged | 2018 |
Age- and disease-specific changes of the kynurenine pathway in Parkinson's and Alzheimer's disease.
Topics: Aged; Aging; Alzheimer Disease; Female; Humans; Kynurenine; Male; Middle Aged; Parkinson Disease | 2019 |
3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Female; Glutathione; Humans; Kynurenine; Male; Mass Spec | 2013 |
Metabolomics and the search for biomarkers in Parkinson's disease.
Topics: Female; Humans; Kynurenine; Male; Oxidative Stress; Parkinson Disease | 2013 |
LC-MS-based urinary metabolite signatures in idiopathic Parkinson's disease.
Topics: alpha-Synuclein; Animals; Biomarkers; Chromatography, Liquid; Drosophila melanogaster; Fatty Acids; | 2015 |
Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease.
Topics: Adaptation, Physiological; Aged; Brain; Erythrocytes; Female; Humans; Kynurenic Acid; Kynurenine; Ma | 2005 |
Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration.
Topics: Aged; Dopamine; Humans; Hydroxyindoleacetic Acid; Kynurenine; Levodopa; Middle Aged; Parkinson Disea | 1993 |
Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms.
Topics: 5-Hydroxytryptophan; Humans; Hydroxyindoleacetic Acid; Kynurenine; Middle Aged; Parkinson Disease; R | 1993 |
Increased neopterin production and tryptophan degradation in advanced Parkinson's disease.
Topics: Aged; Chromatography, High Pressure Liquid; Female; Humans; Immunity, Cellular; Kynurenine; Male; Ne | 2002 |
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Energy Metabolism; Free Radicals; Humans; Huntington Disea | 1992 |
Kynurenine pathway abnormalities in Parkinson's disease.
Topics: Aged; Autopsy; Brain; Female; Humans; Kynurenine; Male; Parkinson Disease; Tryptophan; Tyrosine | 1992 |